19:44 , May 9, 2019 |  BC Extra  |  Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy  Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56%...
21:38 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

Pfizer's 20-valent pneumonia vaccine safe, immunogenic in Phase II

Pfizer said its pneumococcal conjugate vaccine 20vPnC (PF-06482077) was safe and led to "robust" immunogenicity in a Phase II trial to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes contained in the product....
16:42 , Jun 8, 2018 |  BC Week In Review  |  Financial News

SutroVax adds Slaoui as chairman, raises $85M series C

SutroVax Inc. (South San Francisco, Calif.) raised $85 million in an oversubscribed series C round led by new investor TPG on a newsy June 7 that also saw the vaccine company appoint Moncef Slaoui chairman...
21:42 , Jun 7, 2018 |  BC Extra  |  Financial News

SutroVax raises $85M, names Slaoui chair

SutroVax Inc. (South San Francisco, Calif.) raised $85 million in an oversubscribed series C round led by new investor TPG on a newsy Thursday that also saw the vaccine company appoint Moncef Slaoui chairman and...
20:56 , May 1, 2018 |  BC Extra  |  Company News

Read says Pfizer not looking toward M&A

Pfizer Inc. (NYSE:PFE) Chairman and CEO Ian Read said the pharma is focusing investments on its own pipeline rather than M&A. "I don't see that we need a transformative deal, nor do I see one...
18:26 , Feb 16, 2018 |  BioCentury  |  Emerging Company Profile

Synthetic speed

Vaxxilon AG is developing synthetic carbohydrate vaccines for bacterial infections that are designed to be quicker and less expensive to manufacture, and easier to store than traditional conjugate vaccines. “It’s an order of magnitude different...
19:50 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pneumococcus Rabbit studies suggest a vaccine based on an S. pneumoniae CPS mimic could help prevent invasive pneumococcal disease caused by the pathogen's serotype 5. The vaccine consisted of a synthetic oligosaccharide mimic of...
00:54 , Mar 25, 2017 |  BioCentury  |  Finance

Beyond Prevnar

Frazier Healthcare Partners had been tracking SutroVax Inc. 's progress since it spun out of Sutro Biopharma Inc. in 2013 and came on board to co-lead the company's $60 million series B round after preclinical...
01:48 , Mar 4, 2017 |  BioCentury  |  Finance

VCs need not apply

After sealing its second deal with Astellas Pharma Inc. (Tokyo:4503) last week, Affinivax Inc. says it can continue to build its pipeline without any venture money. Founded in 2014, the vaccine company has sustained itself...
18:31 , Nov 18, 2016 |  BC Week In Review  |  Company News

Prevenar 13 sales and marketing update

Pfizer said it expanded an assistance program to provide its Prevenar 13 vaccine in humanitarian crisis settings. Pfizer will supply the product’s new multi-dose vial at $3.10 per dose and will donate first-year sales from...